Y
Yiren Hu
Researcher at Wenzhou Medical College
Publications - 7
Citations - 87
Yiren Hu is an academic researcher from Wenzhou Medical College. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 2, co-authored 4 publications receiving 36 citations. Previous affiliations of Yiren Hu include Wannan Medical College.
Papers
More filters
Journal ArticleDOI
lncRNA GCAWKR Promotes Gastric Cancer Development by Scaffolding the Chromatin Modification Factors WDR5 and KAT2A
TL;DR: Levels of the GCAWKR were upregulated in GC tissues compared with normal tissues and associated with tumor size, lymph node metastasis, TNM stage, and patient outcomes, suggesting new therapeutic targets in GC.
Journal ArticleDOI
Systemic inflammation score is a prognostic marker after curative resection in gastric cancer.
TL;DR: The systemic inflammation score, as calculated from preoperative serum albumin level and lymphocyte‐to‐monocyte ratio, has been demonstrated to be a prognostic marker in cancer.
Journal ArticleDOI
Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer.
Ming zhe Ma,Pengfei Kong,Yakai Huang,Jiangli Wang,Xiaocen Liu,Yiren Hu,Xingxing Chen,Chunyan Du,Hui Yang +8 more
TL;DR: In this paper , a link between methionine cycle activity and ferroptosis vulnerability in gastric cancer was established, which indicated that cell metabolism plays an important role in the regulation of ferrotransoxidation.
Journal ArticleDOI
Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer
TL;DR: In this article, the role of methionine metabolism in the activation of TAMs was evaluated with both in vivo analyses and in vitro experiments, where molecular and biological analyses were performed.
Journal ArticleDOI
Construction of a Nomogram Model for Predicting Peritoneal Dissemination in Gastric Cancer Based on Clinicopathologic Features and Preoperative Serum Tumor Markers
TL;DR: Wang et al. as discussed by the authors assessed the diagnostic potential of serum tumor markers and clinicopathologic features, to improve the accuracy of predicting the presence of peritoneal dissemination (PD) in GC patients.